Metabolic targeting of malignant tumors: Small-molecule inhibitors of bioenergetic flux

Recent Patents on Anti-Cancer Drug Discovery

Volumn 6, Issue 1, 2011, Pages 6-14

  Mathupala, Saroj P ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Glycolysis; Metabolic targeting; Metabolism; Metabolite mimetics; Mitochondria; Tumor

Indexed keywords

2 AMINOPYRIDINE; ANTINEOPLASTIC AGENT; BROMOPYRUVIC ACID; DEOXYGLUCOSE; DICHLOROACETIC ACID; DIMESNA; FATTY ACID SYNTHASE INHIBITOR; GLUCOSE TRANSPORTER; GLUTATHIONE; HYPOXIA INDUCIBLE FACTOR; JASMONIC ACID METHYL ESTER; LOCKED NUCLEIC ACID; MANNOHEPTULOSE; NAPHTHYRIDINE DERIVATIVE; PALLADIUM; PYRUVIC ACID DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); RUTHENIUM DERIVATIVE; SMALL INTERFERING RNA; SOMATOMEDIN RECEPTOR; TECHNETIUM 99M; THIOREDOXIN; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN;

ADJUVANT THERAPY; AMINO ACID COMPOSITION; AMINO ACID METABOLISM; ANEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOENERGY; BRAIN CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INHIBITION; CARBOHYDRATE METABOLISM; CELL PH; DIAGNOSTIC IMAGING; DRUG DESIGN; DRUG STRUCTURE; DRUG TARGETING; FATTY ACID METABOLISM; GLYCOLYSIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MITOCHONDRIAL RESPIRATION; NONHUMAN; OXIDATION REDUCTION STATE; PATENT; PRIORITY JOURNAL; TISSUE METABOLISM; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; ENERGY METABOLISM; ENZYME INHIBITORS; GLYCOLYSIS; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NEOPLASMS; SMALL MOLECULE LIBRARIES;

EID: 78650954815     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489211793980114     Document Type: Article

References (84)

1. Pedersen PL. Tumor mitochondria and the bioenergetics of cancer cells. Prog Exp Tumor Res 1978; 22: 190-274.
2. Baggetto LG. Deviant energetic metabolism of glycolytic cancer cells. Biochimie 1992; 74: 959-74.
3. Pedersen PL. Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the Warburg Effect, i.e., elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr 2007; 39: 211-22.
4. Heiden VMG, Cantley LC, Thompson CB. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 2009; 324: 1029-33.
5. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004; 4: 891-9.
6. Gatenby RA, Gillies RJ. Glycolysis in cancer: A potential target for therapy. Int J Biochem Cell Biol 2007; 39: 1358-66.
7. Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 2008; 49 Suppl 2: 24S-42S.
8. Tennant DA, Duran RV, Gottlieb E. Targeting metabolic transfor-mation for cancer therapy. Nat Rev Cancer 2010; 10: 267-77.
9. Sattler UG, Hirschhaeusera F, Mueller-Klieser WF. Manipulation of glycolysis in malignant tumors: Fantasy or therapy? Curr Med Chem 2010; 17: 96-108.
10. Cuezva JM, Ortega AD, Willers I, Sanchez-Cenizo L, Aldea M, Sanchez-Arago M. The tumor suppressor function of mitochondria: Translation into the clinics. Biochim Biophys Acta 2009; 1792: 1145-58.
11. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006; 25: 4633-46.
12. Medina RA, Owen GI. Glucose transporters: expression, regulation and cancer. Biol Res 2002; 35: 9-26.
13. Zhao FQ, Keating AF. Functional properties and genomics of glucose transporters. Curr Genomics 2007; 8: 113-28.
14. Yeluri S, Madhok B, Prasad KR, Quirke P, Jayne DG. Cancer's craving for sugar: An opportunity for clinical exploitation. J Cancer Res Clin Oncol 2009; 135: 867-77.
15. Battini, J.-l. G. L., Manel, N. G. A., Kim, F. J., Kinet, S., Taylor, N., Sitbon, M. Glut-1 as a receptor for HTLV envelops and its uses. US20100056448 (2010).
16. DeLaPaz RL, Patronas NJ, Brooks RA, Smith BH, Kornblith PL, Milam H, et al. Positron emission tomographic study of suppression of gray-matter glucose utilization by brain tumors. AJNR Am J Neuroradiol 1983; 4: 826-9.
17. Di Chiro G, Brooks RA, Patronas NJ, Bairamian D, Kornblith PL, Smith BH, et al. Issues in the in vivo measurement of glucose metabolism of human central nervous system tumors. Ann Neurol 1984; 15 Suppl: S138-46.
18. Pitha, J., Roth, G. S., Hayek, M. G., Massimino, S. P., Ceddia, M. A., Davenport, G. M., Burr, J. R. Mimicking the metabolic effects of caloric restriction by administration of glucose anti-metabolites. US20090253642 (2009).
19. Hayek, M. G., Massimino, S. P., Roth, G. S., Davenport, G. M. Compositions comprising glucose anti-metabolites. US20090252834 (2009).
20. Heaney, A. P., Hui, H. Use of fructose-based therapies for the treatment of cancer. US20090232735 (2009).
21. Lampidis, T. J., Kurtoglu, M., Maher, J. C. Mannose derivatives for killing tumor cells. US20090221698 (2009).
22. Sokoloff B, Eddy WH, Saelhof CC, Beach J. Glucose antagonists in experimental cancer. AMA Arch Pathol 1955; 59: 729-32.
23. Landau BR, Laszlo J, Stengle J, Burk D. Certain metabolic and pharmacologic effects in cancer patients given infusions of 2-deoxy-D-glucose. J Natl Cancer Inst 1958; 21: 485-94.
24. Landau, B. R., Landau, S. Treatment of cancers with 2-deoxygalactose. US20090163442 (2009).
25. Keppler D, Fauler J, Gasser T, Holstege A, Leube K, Schulz-Holstege C, et al. Uridylate-trapping sugar analogs in combination with inhibitors of uridylate synthesis de novo and 5-fluorouridine. Adv Enzyme Regul 1985; 23: 61-79.
26. Smith DF, Keppler DO. 2-Deoxy-D-galactose metabolism in ascites hepatoma cells results in phosphate trapping and glycolysis inhibition. Eur J Biochem 1977; 73: 83-92.
27. Chesney, J., Trent, J. O., Telang, S., Clem, B., Meier, J. Family of PFKFB3 inhibitors with anti-neoplastic activities. US20090074884 (2009).
28. Dax, C., Blonski, C., Azema, L., Sygusch, J. Aldolase inhibiting aromatic compounds. US20090137532 (2009).
29. Gefflaut T, Blonski C, Perie J, Willson M. Class I aldolases: Substrate specificity, mechanism, inhibitors and structural aspects. Prog Biophys Mol Biol 1995; 63: 301-40.
30. Rotem R, Heyfets A, Fingrut O, Blickstein D, Shaklai M, Flescher E. Jasmonates: Novel anticancer agents acting directly and selectively on human cancer cell mitochondria. Cancer Res 2005; 65: 1984-93.
31. Flescher, E., Heyfets, A., Herzberg, M. Combination methods of treating cancer. US20100003346 (2010).
32. Eigenbrodt, E., Mazurek, S., Grimm, H. Use of sugar phosphates, sugar phosphate analogs, amino acids and/or amino acid analogs for modulating the glucolysis-enzyme complex, the malate aspartate shuttle and/or the transaminases. US20090163591 (2009).
33. Scheefers, H. Compounds for modulating the glycolysis enzyme complex and/or the transaminase complex. US20090149415 (2009).
34. Mathupala SP, Colen CB, Parajuli P, Sloan AE. Lactate and malignant tumors: A therapeutic target at the end stage of glycolysis. J Bioenerg Biomembr 2007; 39: 73-7.
35. Zerangue, N., Bhat, L. Monocarboxylate transporters expressed in cancer cells. US20090092553 (2009).
36. Friedman, L. S., Francis-lang, H., Parks, A. L., Shaw, K. J., Bjerke, L. M., Heuer, T. S. Pfks as modifiers of the IGFR pathway and methods of use. US20090142272 (2009).
37. Mcswiggen, J., Beigelman, L. RNA interference mediated inhibition of MYC and/or MYB gene expression using short interfering nucleic acids (siRNA). US7659389 (2009).
38. Aicher, T. D., Boyd, S. A., Chicarelli, M. J., Condroski, K. R., Hinklin, R. J., Singh, A. 2-Aminopyridine analogs as glucokinase activators. US20090156603 (2009).
39. Polisetti, D. R., Kodra, J. T., Lau, J., Bloch, P., Guzel, M., Santhosh, K. C., Mjalli, A. M. M., Andrews, R. C., Subramanian, G., Ankersen, M., Vedso, P., Murray, A., Jeppesen, L., Lau, J. Aryl carbonyl derivatives as therapeutic agents. US7541373 (2009).
40. Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torbenson MS, et al. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun 2004; 324: 269-75.
41. Ko, Y. H., Geschwind, J.-f. H., Pedersen, P. L. Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production. 20090326068 (2009).
42. Robey RB, Hong R, Zhong L, Feng L, Zhang H. Effects of the anti-tumor agent 3-bromopyruvate (3BrPA) on glycolytic energy metabolism. FASEB J 2007; 21: A1190-a-.
43. Michelakis ED, Webster L, Mackey JR. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer 2008; 99: 989-94.
44. Dang, C. V., Kim, J.-W., Semenza, G. Pyruvate dehydrogenase kinases as therapeutic targets for cancer and ischemic diseases. US20090209618 (2009).
45. Bachynsky, N., Roy, W. Chemically induced intracellular hyperthermia. US20100056643 (2009).
46. Cohen, B. A. Ruthenium compounds and compositions. US20100055044 (2009).
47. Miller, G. M., Wesson, K. E. Hydrogenated pyrido [4,3-b] indoles for the treatment of oxidative stress. US20100029706 (2009).
48. Von Borstel, R. W. Compositions and methods for treatment of mitochondrial diseases. US7582619 (2009).
49. Martin, D. S., Bertino, J. R., Koutcher, J. In vivo energy depleting strategies for killing drug-resistant cancer cells. US7514413 (2009).
50. Semenza GL. HIF-1 inhibitors for cancer therapy: From gene expression to drug discovery. Curr Pharm Des 2009; 15: 3839-43.
51. Guiadeen, D., Hale, J. J., Kothandaraman, S. Novel 1.8-naphthyridine compounds. US20100056563 (2010).
52. Clements, M. J., Debenham, J. S., Hale, J. J., Madsen-duggan, C. B., Walsh, T. F. Substituted 4-hydroxypyrimidine-5-carboxamides. US20090239876 (2009).
53. Alexandru, G., Deshaies, R., Graumann, J. Compositions and methods of treating hypoxia-associated diseases. US20090192084 (2009).
54. Westergaard, M., Thrue, C. A., Rasmussen, F. W., Hansen, H. F. Potent LNA oligonucleotides for the inhibition of HIF-1A expression. US7589190 (2009).
55. Yoon, H., Mao, L., Lee, Y. B., Ahn, C.-h., Jiang, X. Antisense oligonucleotides that inhibit expression of HIF-1. EP1601325 (2009).
56. Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000; 60: 7075-83.
57. Harris, A. L., Ratcliffe, P. J.,Vordermark, D. MN and hypoxia. US20090239247 (2009).
58. Deluca, H. F., Song, J., Clagett-dame, M., Peterson, R. E., Westler, W. M., Sicinski, R. R. Preparation and use of an AH receptor ligand, 2-(1'H-indole-3'carbonyl)-thiazole-4-carboxylic acid methyl ester. EP1365760 (2009).
59. Yang, D. J., Liu, C. W., Yu, D.-f., Kim, E. E. Bisaminoethanethiol-targeting ligand conjugates and compositions. US20100055035 (2010).
60. Lamego, M., Merritt, S., Young, G. Use of microneedles for small molecule metabolite reporter delivery. US20090247984 (2009).
61. Robey IF, Baggett BK, Kirkpatrick ND, Roe DJ, Dosescu J, Sloane BF, et al. Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer Res 2009; 69: 2260-8.
62. Luciani F, Spada M, De Milito A, Molinari A, Rivoltini L, Montinaro A, et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst 2004; 96: 1702-13.
63. Beria, I., Caruso, M., Flygare, J. A., Lupi, V., Perego, R., Polakis, P., Polson, A., Salsa, M., Spencer, S. D., Valsasina, B. Anthra-cycline derivative conjugates, process for their preparation and their use as antitumor compounds. US20100034837 (2010).
64. Bae, Y. H., Na, K., Lee, E. S. pH-sensitive polymeric micelles for drug delivery. US7659314 (2009).
65. Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick JD, et al. Fatty acid synthesis: A potential selective target for antineoplastic therapy. Proc Natl Acad Sci USA 1994; 91: 6379-83.
66. Kuhajda FP. Fatty acid synthase and cancer: New application of an old pathway. Cancer Res 2006; 66: 5977-80.
67. Arrhenius, T., Chen, M., Cheng, J. F., Huang, Y., Nadzan, A. M., Penuliar, R. J., Wallace, D. M., Zhang, L., Lopaschuk, G. D., Dyck, J. R. Malonyl-CoA Decarboxylase inhibitors as metabolic modulators. US20100016259 (2010).
68. Newell, M. K., Newell, E., Villobos-menvey, E. Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor. US7510710 (2009).
69. Butlin, R. J., Caulkett, P. W. R., Johannesson, P., Knerr, L. D., Leach, A., Newcombe, N. J., O'donnell, C. J., Pointon, H.,Wood, J. M. Therapeutic agents-551. US20090105305 (2009).
70. Butlin, R. J., Caulkett, P. W. R., Leach, A., Newcombe, N. J., O'donnell, C. J., Wood, J. M. Therapeutic agents -551. US20090118332 (2009).
71. Kuriyama, M. Composition for promoting ketone compound formation. EP20080739452 (2010).
72. Veech, R. L. Therapeutic compositions. US20090253781 (2009).
73. Baggetto LG, Testa-Parussini R. Role of acetoin on the regulation of intermediate metabolism of Ehrlich ascites tumor mitochondria: Its contribution to membrane cholesterol enrichment modifying passive proton permeability. Arch Biochem Biophys 1990; 283: 241-8.
74. Zachar, Z., Bingham, P. M. Lipoic acid derivatives and their use in treatment of disease. EP1486495 (2009).
75. Thorson, J. S., Fitzgibbon, J. R. High-throughput assay for sugar-mediated drug transport. US20090317829 (2009).
76. Matsui, H. Infusion preparation for cancer patient. EP2135604 (2009).
77. Giles, G. I. The redox regulation of thiol dependent signaling pathways in cancer. Curr Pharm Des 2006; 12: 4427-4443.
78. Hausheer, F. H. Compositions and methods of use of compounds to increase cancer patient survival time. US20090232827 (2009).
79. Park, M.-G., Yoo, S.-k., Jo, I. G., Kwak, T. Method for controlling NAD(P)/NAD(P)H ratio by oxidoreductase. US20090215145 (2009).
80. Chong JA, Tapia-Ramirez J, Kim S, Toledo-Aral JJ, Zheng Y, Boutros MC, et al. REST: A mammalian silencer protein that restricts sodium channel gene expression to neurons. Cell 1995; 80: 949-57.
81. Roopra, A. S., Sutula, T. P., Schoenike, B. Metabolic-based methods for modulating gene expression. US7557085 (2009).
82. Warburg O. On respiratory impairment in cancer cells. Science 1956; 124: 269-70.
83. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-14.
84. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol 1927; 8: 519-30.